Clinical trials for cancer make a comeback after slowdown caused by pandemic -
4122
post-template-default,single,single-post,postid-4122,single-format-standard,bridge-core-2.6.5,qode-news-3.0.2,qode-page-transition-enabled,ajax_fade,page_not_loaded,qode-page-loading-effect-enabled,,qode_grid_1400,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-25.0,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.5.0,vc_responsive,elementor-default,elementor-kit-344

Clinical trials for cancer make a comeback after slowdown caused by pandemic

Clinical trials for cancer make a comeback after slowdown caused by pandemic

CCancer clinical trials in the United States appear to be rebounding after a significant slowdown during the pandemic, researchers say.

For the study, the investigators analyzed data from the Dana-Farber Cancer Institute in Boston and the Tisch Cancer Institute at Mount Sinai Medical School in New York City on more than 4,700 new patients enrolled in clinical trials for new cancer therapies between December 2019 and June 2021, and 467 new clinical trials activated between June 2019 and June 2021.